Cipla arm Mahape facility gets VAI status from USFDA
Mumbai: Cipla has announced that the United States Food and Drugs Administration (USFDA) has classified the current Good Manufacturing Practices (cGMP) inspection at the analytical testing facility of Sitec Labs Limited, wholly owned subsidiary of the Company located in Mahape, Navi Mumbai as Voluntary Action Indicated (VAI).
The inspection was held from 18th to 20th February, 2025. In February, the facility had initially received two observations in Form 483 from the USFDA.
Read also: USFDA issues 2 observations for Cipla arm Mahape facility
An FDA Form 483 is issued to firm management at the conclusion of an inspection when an investigator(s) has observed any conditions that in their judgment may constitute violations of the Food Drug and Cosmetic (FD&C) Act and related Acts.
Established in 1935, Cipla is a global pharmaceutical company focused on agile and sustainable growth, complex generics, and deepening portfolio in its home markets of India, South Africa, North America, and key regulated and emerging markets. It has strengths in the respiratory, anti-retroviral, urology, cardiology, anti-infective, and CNS segments. It has 47 manufacturing sites around the world which produces 50+ dosage forms and 1,500+ products using cutting-edge technology platforms to cater to its 80+ markets.
Read also: Cipla gets CDSCO Panel nod to study Revefenacin Inhalation solution
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.